Earendil Labs, the international arm of Huashen Intelligent Medicine and a trailblazer in AI biotechnology, has successfully concluded multiple rounds of financing, amassing a total of $787 million. This feat marks the highest funding achievement for a global biotechnology firm in the current year, with participation from esteemed investors including Dimension Capital and DST Global.

The capital injection will fuel the acceleration of Earendil Labs' AI-driven research and development platform, facilitate team expansion, and propel forward antibody and biologic projects. The ultimate goal is to deliver groundbreaking medications for patients grappling with severe illnesses. Earendil Labs has seamlessly woven AI technology throughout the entire biologic development process, and its proprietary platform has already yielded over 40 R&D initiatives. Its strategic partnership with Sanofi has further underscored the platform's efficacy in enhancing productivity and executing R&D endeavors.

Armed with this new funding, Earendil Labs is poised to intensify its AI-driven R&D pursuits, bolster its workforce, drive internal projects to fruition, and forge deeper collaborations. The aim is to offer a wider array of innovative biologics to patients across the globe.